Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BAY 44-3428: Discontinued Development

AXPH is funding a Phase II trial of a second generation tryptase inhibitor, APC 2059,

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE